The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Clinigen Ltd’s portfolio of Established Medicines
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
![](https://www.greenhill.com/sites/default/files/greece-uk.png)
Clinigen Ltd’s Lamda Laboratories
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Clinigen Ltd’s Proleukin
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
![](https://www.greenhill.com/sites/default/files/uk-japan.png)
Kyowa Kirin International’s established medicines business
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
brsk
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising brsk, a UK-based alternative network broadband provider, on its first debt-raise of £178m from Ares Management, a leading global alternative investment manager
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Netomnia
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Netomnia, a leading UK-based fiber operator, on its £295m fundraise led by DigitalBridge Investment Management with follow-on commitments from existing shareholders Soho Square Capital LLP and Advencap Limited
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Theramex
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Acacia Pharma Group plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Netomnia
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Netomnia, a UK-based fibre operator, on its first large-scale fundraise of £123m
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Pulsant Limited
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised Antin Infrastructure Partners on its acquisition of Pulsant from Oak Hill and Scottish Equity Partners. Pulsant is a hybrid cloud specialist, with a nationwide network of 10 data centres across the UK delivering secure, scalable and resilient cloud, colocation and networking services
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Tate & Lyle PLC’s Primary Products business in North America and Latin America (50% stake)
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Tate & Lyle PLC, a leading UK-based global provider of food and beverage ingredients and solutions, on its sale of a controlling stake in its Primary Products business in North America and Latin America
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Equiniti Group PLC
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Siris Capital, a private equity firm focused on the technology sector, on its recommended 180p cash offer for Equiniti Group PLC, a technology-led services and payments specialist
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
Acacia Pharma Group plc
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Biogix, Inc.
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
![Sweden Sweden flag](https://www.greenhill.com/sites/default/files/sweden.gif)
VX Fiber
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised VX Fiber, an international infrastructure and technology business focused on Fibre-to-the-Home networks, on its sale to the infrastructure fund AMP Capital
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Community Fibre Limited
![USA/Germany U.S.A., Germany flags](https://www.greenhill.com/sites/default/files/usa_germany.gif)
Advised Warburg Pincus LLC and Deutsche Telekom Capital Partners on the acquisition of a majority stake in CommunityFibre Limited, a leading full fibre network infrastructure platform in UK
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Cello Health plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States
![Saudi Arabia Saudi Arabia Flag](https://www.greenhill.com/sites/default/files/saudiarabia.gif)
Equity stake in Bupa Arabia
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Global rights (excluding North America) to ThermaCare (United Kingdom)
![Italy Italy flag](https://www.greenhill.com/sites/default/files/italy.gif)
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Asia and US rights to Physiogel
![South Korea Korea flag](https://www.greenhill.com/sites/default/files/Korea.jpg)
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Renewi Canada
![Netherlands Netherlands flag](https://www.greenhill.com/sites/default/files/niederland.gif)
Advised Renewi plc, a leading waste to product company, on the sale of its Canadian operations to Convent Capital, an Amsterdam-based investment firm
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Pfizer Inc. Consumer Health Business
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Assets owned by GlaxoSmithKline plc
![](https://www.greenhill.com/sites/default/files/uk_india_flags.png)
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Concordia International Corp.
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt